US biotech major Biogen (Nasdaq: BIIB) saw its shares slip 2% in pre-market trading, after the company posted first-quarter 2016 financial results that missed analysts’ sales expectations. However, by mid-morning the stock was up 4.7% at $278.44
Revenue rose 6.6% to $2.73 billion from $2.56 billion, missing the FactSet consensus forecasts of $2.74 billion, boosted by growing demand for its multiple sclerosis treatment Tecfidera (dimethyl fumarate).
Net income attributable to the U.S. biotechnology company rose to $970.9 million, or earnings per share of $4.43 per share, in the first quarter ended March 31, from $822.5 million, or $3.49 per share, a year earlier. On an adjusted basis, the company earned $4.79 per share, compared with the FactSet consensus of $4.44.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze